Audentes Therapeutics (NASDAQ:BOLD) PT Lowered to $19.00 at Wells Fargo & Co

Audentes Therapeutics (NASDAQ:BOLD) had its price objective reduced by stock analysts at Wells Fargo & Co from $20.00 to $19.00 in a research note issued on Tuesday, BenzingaRatingsTable reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Wells Fargo & Co‘s target price indicates a potential downside of 33.59% from the company’s previous close.

Other research analysts have also recently issued reports about the company. Evercore ISI upgraded Audentes Therapeutics from an “in-line” rating to an “outperform” rating in a report on Wednesday, November 27th. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 price target on shares of Audentes Therapeutics in a report on Sunday, October 6th. BMO Capital Markets downgraded Audentes Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday. BidaskClub downgraded Audentes Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, November 8th. Finally, Robert W. Baird raised Audentes Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and six have issued a buy rating to the company. Audentes Therapeutics has a consensus rating of “Hold” and an average target price of $43.57.

BOLD opened at $28.61 on Tuesday. The firm has a market capitalization of $1.33 billion, a PE ratio of -8.41 and a beta of 1.77. Audentes Therapeutics has a twelve month low of $17.95 and a twelve month high of $41.65. The firm’s 50-day moving average price is $27.71 and its 200 day moving average price is $33.11.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.07. During the same quarter in the previous year, the firm posted ($0.97) EPS. Equities analysts anticipate that Audentes Therapeutics will post -4.13 EPS for the current year.

In related news, CEO Matthew R. Patterson sold 14,426 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $30.00, for a total value of $432,780.00. Following the sale, the chief executive officer now directly owns 127,820 shares in the company, valued at approximately $3,834,600. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Louis G. Lange sold 10,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $32.16, for a total transaction of $321,600.00. Following the completion of the sale, the director now owns 276,044 shares in the company, valued at $8,877,575.04. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Metropolitan Life Insurance Co NY boosted its position in shares of Audentes Therapeutics by 15.1% during the third quarter. Metropolitan Life Insurance Co NY now owns 14,453 shares of the biotechnology company’s stock worth $406,000 after buying an additional 1,897 shares during the period. Millennium Management LLC grew its stake in shares of Audentes Therapeutics by 49.2% in the third quarter. Millennium Management LLC now owns 773,279 shares of the biotechnology company’s stock valued at $21,721,000 after buying an additional 255,086 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of Audentes Therapeutics by 102.0% in the third quarter. Squarepoint Ops LLC now owns 105,053 shares of the biotechnology company’s stock valued at $2,951,000 after buying an additional 53,053 shares in the last quarter. Barclays PLC raised its holdings in shares of Audentes Therapeutics by 21.8% in the 3rd quarter. Barclays PLC now owns 38,386 shares of the biotechnology company’s stock valued at $1,078,000 after buying an additional 6,861 shares during the period. Finally, Point72 Asset Management L.P. raised its holdings in shares of Audentes Therapeutics by 7.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 241,100 shares of the biotechnology company’s stock valued at $6,772,000 after buying an additional 17,483 shares during the period. Institutional investors and hedge funds own 98.08% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Read More: Systematic Risk

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.